바이오인프라

199730KOSDAQ

43.5 / 100

Reference Date: 2026-09-08

Financial Score19.0 / 40

News Sentiment12.5 / 25

Momentum2.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Plunged 21.1% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

BioInfral is a CRO established in 2007, specializing in bioequivalence testing for generic drugs, Phase I clinical trials for improved drugs, approval clinical trials, immunoassays, and pharmaceutical quality inspections. The company operates multiple business units, including PK, Clinical, Immunoassay, and Testing, offering diverse services such as drug interaction studies, clinical trial management, biomarker analysis, and stability testing.

Number of Employees

141people

Average Salary

47.8M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

0.40Industry Average 1.207.0Point

Half of industry avg (excellent)

ROE

-41.45Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

4.88Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20250.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼11.9% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼257.3% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -15.6% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 1,342Won52-week high 5,42052-week low 1,342

1-month return0.0Point

1m -21.06% (strong drop)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral반기보고서 (2026.06)2026-08-12